RayKnowChina Research Map
Shortlist0

GuangzhouSouthern Medical University

Zhujiang Hospital

南方医科大学珠江医院

Listed for 14 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Zhujiang Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌11 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
  3. Hepatocellular carcinoma肝细胞癌54 papers led5 open trials led
  4. Stomach cancer胃癌10 papers led
  5. Retinoblastoma视网膜母细胞瘤1 paper led
  6. Chordoma脊索瘤1 paper led
  7. Osteosarcoma骨肉瘤9 papers led
  8. Neuroblastoma神经母细胞瘤6 papers led
  9. Multiple myeloma多发性骨髓瘤2 papers led3 open trials led
  10. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led2 open trials led
  11. Beta thalassaemiaβ 地中海贫血1 paper led
  12. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  13. IgA nephropathyIgA 肾病2 papers led
  14. Hirschsprung disease先天性巨结肠5 papers led

Not listed for: Hepatoblastoma, Gastrointestinal stromal tumour, Ewing sarcoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 11 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
11
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 2220212022: 2220222023: 1120232024: 2220242025: 442025

23 hospitals in Guangzhou for nasopharyngeal carcinoma176 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06455410

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 7 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AISide effects & quality of lifeRecurrent / metastatic disease
Departments in papersMedical oncologyENT / head & neck surgeryPediatricsPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led11
  1. Exploring lipid metabolism-associated gene biomarkers and their regulatory mechanisms in nasopharyngeal carcinoma.2025Cancer biomarkers : section A of Disease markersFree full text
  2. Bidirectional regulation of reactive oxygen species for radiosensitization in nasopharyngeal carcinoma.2025Journal of nanobiotechnologyFree full text
  3. Mechanism of skull base osteoradionecrosis explored through laboratory assessment with propensity score-matched analysis.2025Scientific reportsFree full text
  4. A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning.2025eLifeFree full text
  5. Development and validation of a radiosensitivity model to evaluate radiotherapy benefits in pan-cancer.2024Cancer scienceFree full text
  6. Homologous recombination deficiency (HRD) is associated with better prognosis and possibly causes a non-inflamed tumour microenvironment in nasopharyngeal carcinoma.2024The journal of pathology. Clinical researchFree full text
  7. PinX1-Promoted Autophagy Inhibits Cell Proliferation and Induces Cell Apoptosis by Inhibiting the NF-κB/p65 Signaling Pathway in Nasopharyngeal Carcinoma.2023Frontiers in bioscience (Landmark edition)
  8. Nasopharyngeal cancer cell-derived exosomal PD-L1 inhibits CD8+ T-cell activity and promotes immune escape.2022Cancer scienceFree full text
  9. Exosomal LBH inhibits epithelial-mesenchymal transition and angiogenesis in nasopharyngeal carcinoma via downregulating VEGFA signaling.2022International journal of biological sciencesFree full text
  10. Limb-bud and heart (LBH) inhibits cellular migration, invasion and epithelial-mesenchymal transition in nasopharyngeal carcinoma via downregulating αB-crystallin expression.2021Cellular signalling
  11. Preparation of FA-targeted magnetic nanocomposites co-loading TFPI-2 plasmid and cis-platinum and its targeted therapy effects on nasopharyngeal carcinoma.2021International journal of medical sciencesFree full text
Chinese-language papers (not in the count)1
  1. [Skull base defect reconstruction after surgery for recurrent nasopharyngeal carcinoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
All its trials on ClinicalTrials.gov, any status3
  1. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Lead sponsorStart 2022-03
  2. GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06455410Study sitePhase 2Start 2024-06
  3. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
More papers found outside PubMed (not counted)11
  1. 1370P Long-term outcomes of paclitaxel, cisplatin, and capecitabine vs. cisplatin and fluorouracil as induction chemotherapy in nasopharyngeal carcinoma: A multicenter randomized clinical trial2025Annals of Oncologyarticle
  2. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  3. Author response: A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning2025eLifepeer-review
  4. Omission of concurrent chemotherapy in and out of a phase III randomized controlled trial for stage II nasopharyngeal carcinoma.2025Journal of Clinical Oncologyconference-abstract
  5. A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning2024eLifepreprint
  6. A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning2024eLifepreprint
  7. Author response: A multi-gene predictive model for the radiation sensitivity of nasopharyngeal carcinoma based on machine learning2024eLifepeer-review
  8. Neoadjuvant docetaxel-cisplatin followed by concurrent chemoradiotherapy and adjuvant tislelizumab for locally advanced nasopharyngeal carcinoma: A multicenter, single-arm, phase II trial.2024Journal of Clinical Oncologyconference-abstract
  9. SPP1+ tumor-associated macrophages induce radioresistance of nasopharyngeal carcinoma through crosstalk with the tumor microenvironment2024bioRxiv (Cold Spring Harbor Laboratory)preprint
  10. Cancer stem-like cells of nasopharyngeal carcinoma express CXCR4 and display highly invasive activity2022Research Squarepreprint
  11. Retraction Note: CDK4 and miR-15a comprise an abnormal automodulatory feedback loop stimulating the pathogenesis and inducing chemotherapy resistance in nasopharyngeal carcinoma2021BMC Cancerretraction

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 1120232024: 0020242025: 222025

11 hospitals in Guangzhou for oesophageal squamous cell carcinoma191 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImmunotherapyNeoadjuvant & combined treatmentMolecular markers & genomics
Departments in papersRadiation oncologyGastroenterology / hepatologyMedical oncology

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 54 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
54
2021–2025
Trials led
13
any status, ClinicalTrials.gov
Open trials led
5
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 9920212022: 131320222023: 9920232024: 7720242025: 15152025

14 hospitals in Guangzhou for hepatocellular carcinoma192 hospitals in China for hepatocellular carcinoma

Open trials with this hospital 10

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort Study
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06861114

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  2. Recruiting
    Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of Recurrence
    Phase
    Phase 2/Phase 3
    Started
    2024-11
    Registry
    NCT06644937

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  3. Recruiting
    Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
    Phase
    Not given
    Started
    2023-11
    Registry
    NCT06157060

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 3 listed hospitals as study sitesGuangzhou

  4. Not yet recruiting
    Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
    Phase
    Not given
    Started
    2024-04
    Registry
    NCT06317896

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou

  5. Not yet recruiting
    Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06449846

    Age 18 years to 75 years (registered criteria)

    Led by Zhujiang Hospital; 1 listed hospital as study siteGuangzhou

  6. Recruiting
    Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
    Phase
    Not given
    Started
    2025-09
    Registry
    NCT07170345

    Age 18 years to 18 years (registered criteria)

    Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou, Zhuhai

  7. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

  8. Recruiting
    Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.
    Phase
    Phase 3
    Started
    2023-05
    Registry
    NCT05862337

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Lanzhou, Luzhou, Nanchang, Nanchong, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Taizhou, Tianjin, Urumqi, Wenzhou, Xi'an, Zhengzhou

  9. Recruiting
    Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-11
    Registry
    NCT05024214

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Bengbu, Changchun, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Shanghai, Shenyang, Tianjin, Zhengzhou, Zhuhai

  10. Not yet recruiting
    The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
    Phase
    Not given
    Started
    2026-07
    Registry
    NCT07724951

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 6 listed hospitals as study sitesGuangzhou, Harbin, Nanning, Qingdao, Shanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesSurgery & liver transplantRecurrence & prognosisImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicineMedical oncologyRadiation oncology
Papers it led54
  1. Integrin β4-Enriched Small Extracellular Vesicle as Drug Delivery Vehicle for Targeting Pulmonary Metastasis of Hepatocellular Carcinoma.2025Advanced healthcare materialsFree full text
  2. Biomimetic Co-delivery of Lenvatinib and FePt Nanoparticles for Enhanced Ferroptosis/Apoptosis Treatment of Hepatocellular Carcinoma.2025Advanced healthcare materialsFree full text
  3. How to Perform Laparoscopic Right Posterior Sectionectomy when the Right Intersectional Plane is not Always Flat.2025Annals of surgical oncology
  4. Primary liver cancer disease burden in Cambodia during 1990-2021: a systematic analysis of datasets from the global burden of disease study 2021.2025BMC gastroenterologyFree full text
  5. Development and validation of a nomogram for predicting early recurrence in patients undergoing different courses of postoperative adjuvant transarterial chemoembolisation.2025BMC gastroenterologyFree full text
  6. STOX1 Isoform A Promotes Proliferation and Progression of Hepatocellular Carcinoma by Dual Mechanisms of Transcriptionally Upregulation of Cyclin B1 and Activation of ROS-Dependent PTEN/AKT1 Signaling.2025Cancer medicineFree full text
  7. Identification of Tumor Antigens and Immune Subtypes in Hepatocellular Carcinoma From a Multiomics Perspective.2025Cancer reports (Hoboken, N.J.)Free full text
  8. Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma.2025Cancer researchFree full text
  9. The application of augmented reality combined with indocyanine green fluorescence for guiding laparoscopic right hemihepatectomy in the treatment of hepatocellular carcinoma.2025European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  10. Nanoparticle-mediated dual targeting of stromal and immune components to overcome fibrotic and immunosuppressive barriers in hepatocellular carcinoma.2025Journal of controlled release : official journal of the Controlled Release Society
  11. Synchronous portal vein embolization of terminal branches with transcatheter arterial chemoembolization before planned major hepatectomy for hepatitis B virus-related hepatocellular carcinoma: a single-center retrospective cohort study.2025Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  12. Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma.2025Nature communicationsFree full text
  13. Efficacy of combined TAE, HAIC, targeted, and immunotherapy in unresectable HCC: a multicenter propensity score matching study.2025Scientific reportsFree full text
  14. Single-Port Robotic Resection of Recurrent Hepatocellular Carcinoma in the Right Anterior Lobe: A Case Report.2025The international journal of medical robotics + computer assisted surgery : MRCAS
  15. Donafenib versus sorafenib in triple therapy for unresectable hepatocellular carcinoma: a propensity score-matched multicenter analysis.2025World journal of surgical oncologyFree full text
  16. NIR-II Photoacoustic Imaging-Guided Oxygen Delivery and Controlled Release Improves Photodynamic Therapy for Hepatocellular Carcinoma.2024Advanced materials (Deerfield Beach, Fla.)
  17. ASO Author Reflections: Laparoscopic Right Posterior Sectionectomy with Preservation of Subsegment Using Digital Intelligence Liver Surgery Technologies in Patients with HCC After Conversion Therapy.2024Annals of surgical oncology
  18. Laparoscopic Right Posterior Sectionectomy with Preservation of Subsegment Using Augmented Reality Navigation Plus ICG Fluorescence Imaging in Patients with HCC After Conversion Therapy.2024Annals of surgical oncology
  19. A N7-methylguanosine modified circular RNA, circIPP2A2, promotes malignant behaviors in hepatocellular carcinoma by serving as a scaffold in modulating the Hornerin/PI3K/AKT/GSK3β axis.2024Cell death & diseaseFree full text
  20. Laparoscopic anatomic segment Ⅷ resection for hepatocellular carcinoma using the augmented reality-assisted navigation and indocyanine green fluorescence imaging.2024Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  21. Efficacy of Augmented Reality Combined with Indocyanine Green Fluorescence Imaging Guided Laparoscopic Segmentectomy for Hepatocellular Carcinoma.2024Journal of the American College of Surgeons
  22. Perfusion of hepatocellular carcinomas measured by diffusion-derived vessel density biomarker: Higher hepatocellular carcinoma perfusion than earlier intravoxel incoherent motion reports.2024NMR in biomedicine
  23. Enhanced glypican-3-targeted identification of hepatocellular carcinoma with liver fibrosis by pre-degrading excess fibrotic collagen.2023Acta biomaterialia
  24. Aberrant expression of circular RNA DHPR facilitates tumor growth and metastasis by regulating the RASGEF1B/RAS/MAPK axis in hepatocellular carcinoma.2023Cellular oncology (Dordrecht, Netherlands)Free full text
  25. Gadoxetic Acid-Enhanced MRI-Based Radiomics Signature: A Potential Imaging Biomarker for Identifying Cytokeratin 19-Positive Hepatocellular Carcinoma.2023Computational and mathematical methods in medicineFree full text
  26. Deep learning nomogram based on Gd-EOB-DTPA MRI for predicting early recurrence in hepatocellular carcinoma after hepatectomy.2023European radiologyFree full text
  27. Role of exosomes in the development of the immune microenvironment in hepatocellular carcinoma.2023Frontiers in immunologyFree full text
  28. HERC2 promotes inflammation-driven cancer stemness and immune evasion in hepatocellular carcinoma by activating STAT3 pathway.2023Journal of experimental & clinical cancer research : CRFree full text
  29. Augmented Reality Navigation System and Indocyanine Green Fluorescence Imaging Make Laparoscopic Right Anterior Sectionectomy More Precisely and Safely.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  30. Laparoscopic modular extended right posterior sectionectomy for hepatocellular carcinoma guided by projection plane extension from the right hepatic vein.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  31. Perioperative and Disease-Free Survival Outcomes after Hepatectomy for Centrally Located Hepatocellular Carcinoma Guided by Augmented Reality and Indocyanine Green Fluorescence Imaging: A Single-Center Experience.2023Journal of the American College of Surgeons
  32. ASO Author Reflections: Laparoscopic in situ Anatomical Mesohepatectomy for Solitary Massive HCC Using Combined Intrafascial and Extrafascial Approaches with Indocyanine Green Navigation: A New Era of Digital Intelligent Liver Surgery.2022Annals of surgical oncology
  33. Laparoscopic in Situ Anatomical Mesohepatectomy for Solitary Massive HCC Using Combined Intrafascial and Extrafascial Approaches With Indocyanine Green Navigation (with Video).2022Annals of surgical oncology
  34. A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment.2022BMC cancerFree full text
  35. Identification of chromosomal instability-associated genes as hepatocellular carcinoma progression-related biomarkers to guide clinical diagnosis, prognosis and therapy.2022Computers in biology and medicine
  36. Low concentration triphenyl phosphate fuels proliferation and migration of hepatocellular carcinoma cells.2022Environmental toxicology
  37. Deep convolutional neural network for preoperative prediction of microvascular invasion and clinical outcomes in patients with HCCs.2022European radiology
  38. Case report: Primary hepatocellular carcinoma with portal vein tumor thrombus characterized by active tumor immune microenvironment achieving a complete response following treatment of combined immunotherapy.2022Frontiers in immunologyFree full text
  39. Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  40. Actin-related protein 2/3 complex subunit 2-enriched extracellular vesicles drive liver cancer metastasis.2022Hepatology international
  41. LECT2: A pleiotropic and promising hepatokine, from bench to bedside.2022Journal of cellular and molecular medicineFree full text
  42. Targeted-detection and sequential-treatment of small hepatocellular carcinoma in the complex liver environment by GPC-3-targeted nanoparticles.2022Journal of nanobiotechnologyFree full text
  43. A microenvironment-responsive FePt probes for imaging-guided Fenton-enhanced radiotherapy of hepatocellular carcinoma.2022Journal of nanobiotechnologyFree full text
  44. Smp24, a Scorpion-Venom Peptide, Exhibits Potent Antitumor Effects against Hepatoma HepG2 Cells via Multi-Mechanisms In Vivo and In Vitro.2022ToxinsFree full text
  45. Plasmonic-doped melanin-mimic for CXCR4-targeted NIR-II photoacoustic computed tomography-guided photothermal ablation of orthotopic hepatocellular carcinoma.2021Acta biomaterialia
  46. Comprehensive analysis of an immune-related ceRNA network in identifying a novel lncRNA signature as a prognostic biomarker for hepatocellular carcinoma.2021AgingFree full text
  47. Minimally invasive photothermal ablation assisted by laparoscopy as an effective preoperative neoadjuvant treatment for orthotopic hepatocellular carcinoma.2021Cancer letters
  48. Identification and Characterization of Alcohol-related Hepatocellular Carcinoma Prognostic Subtypes based on an Integrative N6-methyladenosine methylation Model.2021International journal of biological sciencesFree full text
  49. Anlotinib followed by transarterial chemoembolization and radiofrequency ablation is a safe and effective initial treatment for hepatocellular carcinoma patients with portal vein tumor thrombus: A retrospective case series study.2021Journal of cancer research and therapeutics
  50. Efficacy of Postoperative Adjuvant Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma Patients with Mesenchymal Circulating Tumor Cell.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  51. A multifunctional targeted nanoprobe with high NIR-II PAI/MRI performance for precise theranostics of orthotopic early-stage hepatocellular carcinoma.2021Journal of materials chemistry. B
  52. Metabolic syndrome cannot mask the changes of faecal microbiota compositions caused by primary hepatocellular carcinoma.2021Letters in applied microbiology
  53. ABCC5 facilitates the acquired resistance of sorafenib through the inhibition of SLC7A11-induced ferroptosis in hepatocellular carcinoma.2021Neoplasia (New York, N.Y.)Free full text
  54. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.2020Frontiers in immunologyFree full text
Chinese-language papers (not in the count)2
  1. [Research progress of radiomics in hepatocellular carcinoma].2024Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [Antitumor effects of AZD2014, a dual mTORC1/2 inhibitor, against human hepatocellular carcinoma xenograft in nude mice].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status22
  1. Exploring the Value of Urine Proteomics-based Dynamic Surveillance for Early Recurrence After Radical Surgery for Hepatocellular Carcinoma: a Prospective Cohort StudyRecruitingNCT06861114Lead sponsorStart 2025-02
  2. Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCSNot yet recruitingNCT06317896Lead sponsorStart 2024-04
  3. Single-arm Clinical Trial of TACE in Combination With Icaritin as Adjuvant Therapy After Surgery in Patients With Hepatocellular Carcinoma at High Risk of RecurrenceRecruitingNCT06644937Lead sponsorPhase 2/Phase 3Start 2024-11
  4. Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular CarcinomaNot yet recruitingNCT06449846Lead sponsorStart 2024-06
  5. Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNARecruitingNCT06157060Lead sponsorStart 2023-11
  6. A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or AblationStatus unknownNCT06546280Lead sponsorPhase 2Start 2024-08
  7. Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled TrialStatus unknownNCT05766605Lead sponsorPhase 3Start 2023-01
  8. A Multicenter RCT Study of 3DV Technology in the Diagnosis and Treatment of PLCStatus unknownNCT05118451Lead sponsorN/AStart 2020-07
  9. The Evaluation of Surgical Decisions and Prognosis of the Radiomics and Watson Artificial Intelligence in Patients With Hepatocellular CarcinomaStatus unknownNCT03917017Lead sponsorN/AStart 2019-01
  10. CT Imaging for Guiding PA-TACE for HCCCompletedNCT06156748Lead sponsorStart 2019-10
  11. Application of Watson for Oncology in Hepatocellular Carcinoma SurgeryStatus unknownNCT03904667Lead sponsorStart 2017-01
  12. The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular CarcinomaStatus unknownNCT03793322Lead sponsorPhase 1Start 2017-01
  13. Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic CarcinomaStatus unknownNCT03132740Lead sponsorStart 2017-03
  14. The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical StudyNot yet recruitingNCT07724951Study siteStart 2026-07
  15. Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular InvasionRecruitingNCT07170345Study siteStart 2025-09
  16. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  17. Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Study sitePhase 3Start 2023-05
  18. Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid TumorsRecruitingNCT05024214Study sitePhase 1/Phase 2Start 2021-11
  19. Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)TerminatedNCT04246177Study sitePhase 3Start 2020-05
  20. A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or AblationCompletedNCT04102098Study sitePhase 3Start 2019-12
  21. Radiomics Subtyping to Guide Surgery vs. Maintenance Therapy After HCC DownstagingActive, not recruitingNCT07581769Study siteStart 2018-01
  22. Sirolimus-based Immunosuppression Treatment Regimen for Liver TransplantationStatus unknownNCT03500848Study sitePhase 2/Phase 3Start 2018-05

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 10 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
10
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 1120232024: 4420242025: 222025

16 hospitals in Guangzhou for stomach cancer218 hospitals in China for stomach cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2024-07
    Registry
    NCT06427941

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Hefei, Nanchang, Nanning, Shijiazhuang, Wenzhou, Wuhan, Xuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesImaging & AIPeritoneal spread & advanced diseaseImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyRadiation oncologyPathology / laboratory medicine
Papers it led10
  1. YTHDF2-mediated m6A modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI.2025Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  2. Evaluation of different lymph node classification systems as independent prognosticators in gastric signet ring cell carcinoma.2025World journal of surgical oncologyFree full text
  3. Fusobacterium nucleatum in tumors: from tumorigenesis to tumor metastasis and tumor resistance.2024Cancer biology & therapyFree full text
  4. Technical variety of anastomotic techniques used in proximal gastrectomy with double-tract-reconstruction - a narrative review.2024Langenbeck's archives of surgery
  5. KAT2A Promotes the Succinylation of PKM2 to Inhibit its Activity and Accelerate Glycolysis of Gastric Cancer.2024Molecular biotechnology
  6. Causal association between metabolites and upper gastrointestinal tumors: A Mendelian randomization study.2024Molecular medicine reportsFree full text
  7. Development and Validation of Prognostic Nomograms Based on Lymph Node Ratio for Young Patients with Gastric Cancer: A SEER-Based Study.2023Technology in cancer research & treatmentFree full text
  8. Evaluating the efficacy and microenvironment changes of HER2 + gastric cancer during HLX02 and Endostar treatment using quantitative MRI.2022BMC cancerFree full text
  9. Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery.2022Frontiers in immunologyFree full text
  10. Comprehensive analysis of tumor mutation burden and immune microenvironment in gastric cancer.2021Bioscience reportsFree full text
All its trials on ClinicalTrials.gov, any status6
  1. A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in ChinaStatus unknownNCT05638269Lead sponsorStart 2022-03
  2. To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid TumorsCompletedNCT03159585Lead sponsorPhase 1Start 2017-04
  3. A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT06427941Study sitePhase 1/Phase 2Start 2024-07
  4. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  5. Acupuncture for QoL and Symptoms in Gastric Cancer During Adjuvant ChemotherapyCompletedNCT04360577Study siteN/AStart 2020-05
  6. Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal MetastasisStatus unknownNCT03023436Study sitePhase 3Start 2016-01

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

8 hospitals in Guangzhou for retinoblastoma196 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Papers it led1
  1. Bioinformatics analysis proposes a possible role for long noncoding RNA MIR17HG in retinoblastoma.2024Cancer reports (Hoboken, N.J.)
Earlier papers (2016–2020)2
  1. [DNMT1 protein promotes retinoblastoma proliferation by silencing MEG3 gene].2020Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  2. Decreased expression of MEG3 contributes to retinoblastoma progression and affects retinoblastoma cell growth by regulating the activity of Wnt/β-catenin pathway.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

4 hospitals in Guangzhou for chordoma88 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 9 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 1120232024: 4420242025: 112025

33 hospitals in Guangzhou for osteosarcoma742 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Over half of these papers are lab or animal studies.

Papers it led9
  1. Long noncoding RNA DHRS4 antisense RNA 1 suppresses osteosarcoma cell proliferation and promotes apoptosis through a competitive endogenous RNA mechanism.2025Scientific reports
  2. 3D-Printed Magnesium Peroxide-Incorporated Scaffolds with Sustained Oxygen Release and Enhanced Photothermal Performance for Osteosarcoma Multimodal Treatments.2024ACS applied materials & interfaces
  3. Disulfidoptosis-related molecular subtypes and prognostic model for optimizing drug therapy in metastatic osteosarcoma patients.2024FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  4. Cu-Tremella fuciformis polysaccharide-based tumor microenvironment-responsive injectable gels for cuproptosis-based synergistic osteosarcoma therapy.2024International journal of biological macromolecules
  5. Case report: A case of primary renal osteosarcoma.2024Medicine
  6. Cirsiliol induces autophagy and mitochondrial apoptosis through the AKT/FOXO1 axis and influences methotrexate resistance in osteosarcoma.2023Journal of translational medicine
  7. Characterization of the Tumor Microenvironment in Osteosarcoma Identifies Prognostic- and Immunotherapy-Relevant Gene Signatures.2022Journal of immunology research
  8. Circular RNA 0102049 suppresses the progression of osteosarcoma through modulating miR-520g-3p/PLK2 axis.2021Bioengineered
  9. Circular RNA circ_001422 promotes the progression and metastasis of osteosarcoma via the miR-195-5p/FGF2/PI3K/Akt axis.2021Journal of experimental & clinical cancer research : CR
Earlier papers (2016–2020)8
  1. Therapeutic potential of targeting HSPA5 through dual regulation of two candidate prognostic biomarkers ANXA1 and PSAT1 in osteosarcoma.2020Aging
  2. Knockdown of TBRG4 suppresses proliferation, invasion and promotes apoptosis of osteosarcoma cells by downregulating TGF-β1 expression and PI3K/AKT signaling pathway.2020Archives of biochemistry and biophysics
  3. AgBiS2 nanoparticles with synergistic photodynamic and bioimaging properties for enhanced malignant tumor phototherapy.2020Materials science & engineering. C, Materials for biological applications
  4. Cadmium chloride enhances cisplatin sensitivity in osteosarcoma cells by reducing FOXM1 expression.2020Oncology reports
  5. Enhancing Osteosarcoma Killing and CT Imaging Using Ultrahigh Drug Loading and NIR-Responsive Bismuth Sulfide@Mesoporous Silica Nanoparticles.2018Advanced healthcare materials
  6. Zero-Dimensional Carbon Dots Enhance Bone Regeneration, Osteosarcoma Ablation, and Clinical Bacterial Eradication.2018Bioconjugate chemistry
  7. Hypoxia-inducible microRNA-488 regulates apoptosis by targeting Bim in osteosarcoma.2016Cellular oncology (Dordrecht, Netherlands)
  8. Porous nano-hydroxyapatite/collagen scaffold containing drug-loaded ADM-PLGA microspheres for bone cancer treatment.2016Journal of materials science. Materials in medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 6 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.5%.

Papers led
6
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 3320232024: 1120242025: 112025

23 hospitals in Guangzhou for neuroblastoma352 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatricsNeurology

Over half of these papers are lab or animal studies.

Papers it led6
  1. Identification of key genes related to cancer associated fibroblasts in neuroblastoma: A comprehensive bioinformatics approach.2025Cancer biomarkers : section A of Disease markers
  2. Integrated machine learning-driven disulfidptosis profiling: CYFIP1 and EMILIN1 as therapeutic nodes in neuroblastoma.2024Journal of cancer research and clinical oncology
  3. SYNJ1 rescues motor functions in hereditary and sporadic Parkinson's disease mice by upregulating TSP-1 expression.2023Behavioural brain research
  4. Machine learning methods revealed the roles of immune-metabolism related genes in immune infiltration, stemness, and prognosis of neuroblastoma.2023Cancer biomarkers : section A of Disease markers
  5. The m6A methyltransferase METTL3 affects cell proliferation and migration by regulating YAP expression in Hirschsprung disease.2023Pediatric surgery international
  6. GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients.2022Journal of cancer research and clinical oncology
Earlier papers (2016–2020)3
  1. Tristetraprolin destabilizes NOX2 mRNA and protects dopaminergic neurons from oxidative damage in Parkinson's disease.2020FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  2. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling.2019Cancer letters
  3. Endoscopic surgery for primary sinonasal malignancies: Treatment outcomes and prognostic factors.2018Ear, nose, & throat journal
All its trials on ClinicalTrials.gov, any status1
  1. Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent NeuroblastomaCompletedNCT02765243Lead sponsorPhase 1Start 2016-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
5
any status, ClinicalTrials.gov
Open trials led
3
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

14 hospitals in Guangzhou for multiple myeloma178 hospitals in China for multiple myeloma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Intestinal Flora and Immunity in Monoclonal Gammopathy Patients
    Phase
    Not given
    Started
    2024-05
    Registry
    NCT06539832

    Age 45 years to Not stated (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  2. Recruiting
    Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy
    Phase
    Not given
    Started
    2024-12
    Registry
    NCT06690593

    Age 45 years to Not stated (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  3. Recruiting
    Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS Analysis
    Phase
    Not given
    Started
    2023-01
    Registry
    NCT05686447

    Age not stated (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  4. Recruiting
    A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
    Phase
    Phase 1
    Started
    2026-05
    Registry
    NCT07477587

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 46 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Ningbo, Qingdao, Shanghai, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Weifang, Wenzhou, Wuhan, Wuxi, Xiamen, Xuzhou, Zhengzhou

  5. Not yet recruiting
    Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple Myeloma
    Phase
    Phase 3
    Started
    2026-06
    Registry
    NCT07569757

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengde, Chengdu, Chongqing, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Xi'an, Xuzhou, Zhanjiang, Zhengzhou, Zhuzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRelapse & resistanceDrug combinations
Papers it led2
  1. Overexpression of Pin1 regulated by TOP2A, which subsequently stabilizes Pyk2 to promote bortezomib resistance in multiple myeloma.2025Cancer gene therapy
  2. Targeting PARP14 with lomitapide suppresses drug resistance through the activation of DRP1-induced mitophagy in multiple myeloma.2024Cancer letters
All its trials on ClinicalTrials.gov, any status9
  1. Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal GammopathyRecruitingNCT06690593Lead sponsorStart 2024-12
  2. Intestinal Flora and Immunity in Monoclonal Gammopathy PatientsRecruitingNCT06539832Lead sponsorStart 2024-05
  3. Screening and Therapeutic Monitoring of Multiple Myeloma by MALDI-TOF MS AnalysisRecruitingNCT05686447Lead sponsorStart 2023-01
  4. A Cross-sectional Study on the Positive Rate of M Protein Based on a Highly Sensitive Serum M Protein Detection Method.Status unknownNCT06082284Lead sponsorStart 2023-10
  5. CAR-T Cells Therapy in Relapsed/Refractory Multiple MyelomaTerminatedNCT03473496Lead sponsorN/AStart 2018-03
  6. Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingNCT07569757Study sitePhase 3Start 2026-06
  7. A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple MyelomaRecruitingNCT07477587Study sitePhase 1Start 2026-05
  8. A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)Active, not recruitingNCT06464991Study sitePhase 3Start 2024-03
  9. A Study of Ninlaro in Real World Clinical Practice in ChinaCompletedNCT04328662Study siteStart 2020-05

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

8 hospitals in Guangzhou for B-cell acute lymphoblastic leukaemia90 hospitals in China for B-cell acute lymphoblastic leukaemia

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
    Phase
    Phase 1/Phase 2
    Started
    2025-07
    Registry
    NCT07072494

    Age 14 years to 80 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  2. Not yet recruiting
    Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute Leukemia
    Phase
    Early phase 1
    Started
    2026-08
    Registry
    NCT07696481

    Age 3 years to 75 years (registered criteria)

    Led by Zhujiang HospitalGuangzhou

  3. Recruiting
    Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic Leukemia
    Phase
    Not given
    Started
    2024-06
    Registry
    NCT06450067

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Jinan, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesCAR-T & cell therapyMRD & relapse
Papers it led1
  1. Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients.2024American journal of hematology
Chinese-language papers (not in the count)1
  1. [Safety and efficacy of donor-derived chimeric antigen receptor T-cell therapy in patients with relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].2024Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhiFree full text
All its trials on ClinicalTrials.gov, any status7
  1. Clinical Study on the Safety and Efficacy of PID23 Injection in Patients With Relapsed/Refractory Acute LeukemiaNot yet recruitingNCT07696481Lead sponsorEarly phase 1Start 2026-08
  2. CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical StudyRecruitingNCT07072494Lead sponsorPhase 1/Phase 2Start 2025-07
  3. CD19 CAR T-cell Target Relapsed/Refractory Acute B Cell Leukemia/LymphomaWithdrawnNCT05613348Lead sponsorPhase 1/Phase 2Start 2022-12
  4. Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALLStatus unknownNCT03407859Lead sponsorEarly phase 1Start 2016-01
  5. Inaticabtagene Autoleucel Injection Treatment for Adult Relapsed or Refractory Acute Lymphocytic LeukemiaRecruitingNCT06450067Study siteStart 2024-06
  6. Study of Blinatumomab Administration in Chinese Pediatric Participants With Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)Active, not recruitingNCT06054113Study sitePhase 2Start 2024-07
  7. A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALLActive, not recruitingNCT04521231Study sitePhase 1/Phase 2Start 2021-01

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 1 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

23 hospitals in Guangzhou for beta thalassaemia157 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

13 hospitals in Guangzhou for amyotrophic lateral sclerosis194 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 112025

20 hospitals in Guangzhou for IgA nephropathy346 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Papers it led2
  1. Investigating the genetic effects of metformin-related targets on IgA nephropathy using Mendelian randomization.2025Renal failure
  2. New insights into pathogenesis of IgA nephropathy.2022International urology and nephrology
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Telitacicept for IgA Nephropathy (TELIGAN)Active, not recruitingNCT05799287Study sitePhase 3Start 2023-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led 5 of the 161 English-language PubMed papers on Hirschsprung disease with an author in mainland China, 2021–2025: 3.1%.

Papers led
5
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 2220232024: 2220242025: 002025

8 hospitals in Guangzhou for Hirschsprung disease82 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPediatrics

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

南方医科大学珠江医院

Zhujiang Hospital

广州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Zhujiang Hospital of Southern Medical University; ZhuJiang Hospital; Southern Medical University/Zhujiang Hospital; Zhujiang Hospital Southern Medical University; Southern Medical University Zhujiang Hospital; Zhujiang Hospital of Southern Medcal University; Pediatric Center of Zhujiang Hospital; Otorhinolaryngology of Zhujiang Hospital

Suggest a correctionDownload the data